文献速递胸部CT

基于计算机断层扫描的免疫生态系统多样性指数作为非小细胞肺癌影像生物标志物的开发与验证

Development and validation of a computed tomography-based immune ecosystem diversity index as an imaging biomarker in non-small cell lung cancer.
PubMed 文献 · Eur Radiol · 2022-05-31

回顾性研究利用两个独立非小细胞肺癌队列(Resec1 n=149;Resec2 n=97)的术前CT提取EDI特征开发iEDI以分类瘤内免疫状态,Resec1的AUC为0.771(95%CI 0.759-0.783),Resec2为0.669(95%CI 0.647-0.691);在Resec3(n=419)、Resec4(n=96)和TCIA队列(n=55)中,iEDI-score较高者总生存期更长。iEDI是非侵入性瘤内免疫状态替代指标,对接受手术切除的NSCLC患者具有预后价值。

要点

  • iEDI由术前CT提取的EDI特征构建,用于非侵入性判断瘤内免疫状态。
  • Resec1中iEDI分类免疫状态的AUC为0.771(95%CI 0.759-0.783)。
  • iEDI-score较高的患者总生存期更长,风险比在多个队列中均低于1。

核心结论

  • iEDI是非侵入性瘤内免疫状态替代指标,对接受手术切除的NSCLC患者的总生存期具有预后价值。

研究设计与样本

  • 回顾性研究,两个独立NSCLC队列(Resec1 n=149;Resec2 n=97)用于开发和验证iEDI以分类瘤内免疫状态,Resec1和Resec2的切除标本经免疫组化染色量化CD3+、CD4+和CD8+ T细胞占所有细胞的密度百分位数以评估瘤内免疫状态,并利用术前CT提取EDI特征开发影像生物标志物iEDI;预后价值在Resec1、Resec2、内部队列Resec3(n=419)、外部队列Resec4(n=96)和TCIA队列Resec5(n=55)中研究。

诊断标准与关键数值

  • iEDI在Resec1中分类免疫状态的AUC为0.771(95%CI 0.759-0.783),内部验证AUC为0.770。
  • iEDI在Resec2中分类免疫状态的AUC为0.669(95%CI 0.647-0.691)。
  • Resec3中iEDI-score较高者总生存期更长,未调整风险比0.335(95%CI 0.206-0.546,p<0.001)。
  • Resec4中iEDI-score较高者总生存期更长,未调整风险比0.199(95%CI 0.040-1.000,p<0.001)。
  • TCIA队列中iEDI-score较高者总生存期更长,未调整风险比0.303(95%CI 0.098-0.944,p=0.001)。

临床应用与阅片要点

  • iEDI可作为非侵入性瘤内免疫状态替代指标用于NSCLC患者。
  • iEDI对接受手术切除的NSCLC患者具有总生存期预后价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To date, there are no data on the noninvasive surrogate of intratumoural immune status that could be prognostic of survival outcomes in non-small cell lung cancer (NSCLC). We aimed to develop and validate the immune ecosystem diversity index (iEDI), an imaging biomarker, to indicate the intratumoural immune status in NSCLC. We further investigated the clinical relevance of the biomarker for survival prediction.

METHODS: In this retrospective study, two independent NSCLC cohorts (Resec1, n = 149; Resec2, n = 97) were included to develop and validate the iEDI to classify the intratumoural immune status. Paraffin-embedded resected specimens in Resec1 and Resec2 were stained by immunohistochemistry, and the density percentiles of CD3+, CD4+, and CD8+ T cells to all cells were quantified to estimate intratumoural immune status. Then, EDI features were extracted using preoperative computed tomography to develop an imaging biomarker, called iEDI, to determine the immune status. The prognostic value of iEDI was investigated on NSCLC patients receiving surgical resection (Resec1; Resec2; internal cohort Resec3, n = 419; external cohort Resec4, n = 96; and TCIA cohort Resec5, n = 55).

RESULTS: iEDI successfully classified immune status in Resec1 (AUC 0.771, 95% confidence interval [CI] 0.759-0.783; and 0.770 through internal validation) and Resec2 (0.669, 0.647-0.691). Patients with higher iEDI-score had longer overall survival (OS) in Resec3 (unadjusted hazard ratio 0.335, 95%CI 0.206-0.546, p < 0.001), Resec4 (0.199, 0.040-1.000, p < 0.001), and TCIA (0.303, 0.098-0.944, p = 0.001).

CONCLUSIONS: iEDI is a non-invasive surrogate of intratumoural immune status and prognostic of OS for NSCLC patients receiving surgical resection.

KEY POINTS: • Decoding tumour immune microenvironment enables advanced biomarkers identification. • Immune ecosystem diversity index characterises intratumoural immune status noninvasively. • Immune ecosystem diversity index is prognostic for NSCLC patients.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. He L, Li ZH, Yan LX, et al. Development and validation of a computed tomography-based immune ecosystem diversity index as an imaging biomarker in non-small cell lung cancer. Eur Radiol. 2022. PMID: 35639145. doi:10.1007/s00330-022-08873-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。